New drug vs chemo for advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug (mocertatug rezetecan) compared to standard chemotherapy for people with endometrial cancer that has progressed after platinum-based chemo and immunotherapy. It may help if your tumor has a protein called B7-H4.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have endometrioid, serous, clear cell, or carcinosarcoma endometrial cancer, or a mixed type.
- You've had 1 to 3 prior treatments, including platinum-based chemo and immunotherapy (or you couldn't have immunotherapy due to medical reasons).
- Your tumor tissue must be tested for a protein called B7-H4 to see if it's a good target for the study drug.
- You must have at least one tumor that can be measured on a scan.
- You need to be willing to use effective birth control if there's a chance of pregnancy, and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a new investigational drug called Puxitatug Samrotecan (AZD8205) against standard chemotherapy in people whose endometrial cancer has come back or spread after prior treatment with platinum chemo and an immunotherapy. The goal is to see if the new drug works better.
This trial tests a new drug, mocertatug rezetecan, combined with other anti-cancer therapies for people with advanced solid tumors like endometrial or ovarian cancer. It aims to see if the combination is safe and effective.
This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).
This trial tests a new drug called Mocertatug Rezetecan for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called B7-H4 on cancer cells to try to slow or shrink the tumor.
This trial is testing an experimental therapy against standard chemotherapy for people with endometrial cancer that has come back. The study looks for a certain protein (HER2) on cancer cells to decide which treatment group you may be in.
Hear when a new Neoplasms, Endometrial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.